Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 7,8-didehydro-27-deoxyactein
1. 214146-75-5
2. 7,8-didehydro-27-deoxyactein
3. 9h7xn615a3
4. [(1r,1's,3'r,4s,4'r,5r,5'r,6'r,10's,12's,16'r,18's,21'r)-1,4',6',12',17',17'-hexamethyl-18'-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyspiro[3,6-dioxabicyclo[3.1.0]hexane-4,8'-9-oxahexacyclo[11.9.0.01,21.04,12.05,10.016,21]docos-13-ene]-3'-yl] Acetate
5. Unii-9h7xn615a3
6. Hy-n5088
7. Zinc255257886
8. 26-deoxycimicifugoside, (-)-
9. Cs-0032406
10. Q27272561
11. 26-deoxycimicifugoside (constituent Of Black Cohosh) [dsc]
12. .beta.-d-xylopyranoside, (3.beta.,12.beta.,16.beta.,23s,24r,25r)-12-(acetyloxy)-16,23:23,26:24,25-triepoxy-9,19-cyclolanost-7-en-3-yl
13. Beta-d-xylopyranoside, (3beta,12beta,16beta,23s,24r,25r)-12-(acetyloxy)-16,23:23,26:24,25-triepoxy-9,19-cyclolanost-7-en-3-yl
| Molecular Weight | 658.8 g/mol |
|---|---|
| Molecular Formula | C37H54O10 |
| XLogP3 | 3.1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 4 |
| Exact Mass | 658.37169792 g/mol |
| Monoisotopic Mass | 658.37169792 g/mol |
| Topological Polar Surface Area | 136 Ų |
| Heavy Atom Count | 47 |
| Formal Charge | 0 |
| Complexity | 1410 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 17 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A 26-Deoxycimicifugoside manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 26-Deoxycimicifugoside, including repackagers and relabelers. The FDA regulates 26-Deoxycimicifugoside manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 26-Deoxycimicifugoside API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A 26-Deoxycimicifugoside supplier is an individual or a company that provides 26-Deoxycimicifugoside active pharmaceutical ingredient (API) or 26-Deoxycimicifugoside finished formulations upon request. The 26-Deoxycimicifugoside suppliers may include 26-Deoxycimicifugoside API manufacturers, exporters, distributors and traders.
26-Deoxycimicifugoside Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 26-Deoxycimicifugoside GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 26-Deoxycimicifugoside GMP manufacturer or 26-Deoxycimicifugoside GMP API supplier for your needs.
A 26-Deoxycimicifugoside CoA (Certificate of Analysis) is a formal document that attests to 26-Deoxycimicifugoside's compliance with 26-Deoxycimicifugoside specifications and serves as a tool for batch-level quality control.
26-Deoxycimicifugoside CoA mostly includes findings from lab analyses of a specific batch. For each 26-Deoxycimicifugoside CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
26-Deoxycimicifugoside may be tested according to a variety of international standards, such as European Pharmacopoeia (26-Deoxycimicifugoside EP), 26-Deoxycimicifugoside JP (Japanese Pharmacopeia) and the US Pharmacopoeia (26-Deoxycimicifugoside USP).
LOOKING FOR A SUPPLIER?
